🚀 VC round data is live in beta, check it out!
Daewoong Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Daewoong Pharmaceutical and similar public comparables like ORIC Pharmaceuticals, Idorsia, Concord Biotech, Savara and more.
Daewoong Pharmaceutical Overview
About Daewoong Pharmaceutical
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.
Founded
2002
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$2B
Daewoong Pharmaceutical Financials
Daewoong Pharmaceutical reported last 12-month revenue of $984M and EBITDA of $170M.
In the same LTM period, Daewoong Pharmaceutical generated $517M in gross profit, $170M in EBITDA, and $113M in net income.
Revenue (LTM)
Daewoong Pharmaceutical P&L
In the most recent fiscal year, Daewoong Pharmaceutical reported revenue of $1B and EBITDA of $173M.
Daewoong Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $984M | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $517M | XXX | $557M | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $170M | XXX | $173M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $113M | XXX | $133M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $445M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Daewoong Pharmaceutical Stock Performance
Daewoong Pharmaceutical has current market cap of $1B, and enterprise value of $2B.
Market Cap Evolution
Daewoong Pharmaceutical's stock price is $104.27.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $1B | -1.8% | XXX | XXX | XXX | $11.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDaewoong Pharmaceutical Valuation Multiples
Daewoong Pharmaceutical trades at 1.7x EV/Revenue multiple, and 9.7x EV/EBITDA.
EV / Revenue (LTM)
Daewoong Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, Daewoong Pharmaceutical has market cap of $1B and EV of $2B.
Equity research analysts estimate Daewoong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Daewoong Pharmaceutical has a P/E ratio of 10.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 9.7x | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBIT | 11.8x | XXX | 12.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | 3.0x | XXX | XXX | XXX |
| P/E | 10.6x | XXX | 9.1x | XXX | XXX | XXX |
| EV/FCF | 28.0x | XXX | 37.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Daewoong Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Daewoong Pharmaceutical Margins & Growth Rates
Daewoong Pharmaceutical's revenue in the last 12 month grew by 14%.
Daewoong Pharmaceutical's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Daewoong Pharmaceutical's rule of X is 24% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Daewoong Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 3% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 24% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Daewoong Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Daewoong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| ORIC Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Idorsia | XXX | XXX | XXX | XXX | XXX | XXX |
| Concord Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Savara | XXX | XXX | XXX | XXX | XXX | XXX |
| Guilin Sanjin | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Daewoong Pharmaceutical M&A Activity
Daewoong Pharmaceutical acquired XXX companies to date.
Last acquisition by Daewoong Pharmaceutical was on XXXXXXXX, XXXXX. Daewoong Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Daewoong Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDaewoong Pharmaceutical Investment Activity
Daewoong Pharmaceutical invested in XXX companies to date.
Daewoong Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Daewoong Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Daewoong Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Daewoong Pharmaceutical
| When was Daewoong Pharmaceutical founded? | Daewoong Pharmaceutical was founded in 2002. |
| Where is Daewoong Pharmaceutical headquartered? | Daewoong Pharmaceutical is headquartered in South Korea. |
| Who is the CEO of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's CEO is Chang-Jae Lee. |
| Is Daewoong Pharmaceutical publicly listed? | Yes, Daewoong Pharmaceutical is a public company listed on Korea Exchange. |
| What is the stock symbol of Daewoong Pharmaceutical? | Daewoong Pharmaceutical trades under 069620 ticker. |
| When did Daewoong Pharmaceutical go public? | Daewoong Pharmaceutical went public in 2002. |
| Who are competitors of Daewoong Pharmaceutical? | Daewoong Pharmaceutical main competitors are ORIC Pharmaceuticals, Idorsia, Concord Biotech, Savara. |
| What is the current market cap of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's current market cap is $1B. |
| What is the current revenue of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's last 12 months revenue is $984M. |
| What is the current revenue growth of Daewoong Pharmaceutical? | Daewoong Pharmaceutical revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Daewoong Pharmaceutical? | Current revenue multiple of Daewoong Pharmaceutical is 1.7x. |
| Is Daewoong Pharmaceutical profitable? | Yes, Daewoong Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's last 12 months EBITDA is $170M. |
| What is Daewoong Pharmaceutical's EBITDA margin? | Daewoong Pharmaceutical's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Daewoong Pharmaceutical? | Current EBITDA multiple of Daewoong Pharmaceutical is 9.7x. |
| What is the current FCF of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's last 12 months FCF is $59M. |
| What is Daewoong Pharmaceutical's FCF margin? | Daewoong Pharmaceutical's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Daewoong Pharmaceutical? | Current FCF multiple of Daewoong Pharmaceutical is 28.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.